Canada markets closed

InMed Pharmaceuticals Inc. (INM)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.3640+0.0320 (+9.64%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.3320
Open0.3501
Bid0.3360 x 100
Ask0.3900 x 100
Day's Range0.3405 - 0.3787
52 Week Range0.2910 - 2.0800
Volume59,806
Avg. Volume164,011
Market Cap2.205M
Beta (5Y Monthly)0.47
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

    Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that it has received a notification letter from the Listing Qualifications Department of Nasdaq Stock Market LLC ("Nasdaq") that the Company has been granted an additional 180-day compliance period, or until September 16, 2024

  • Newsfile

    InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

    Advancing two new preclinical programs in Alzheimer's and Age-Related Macular DegenerationClosed calendar year 2023 with cash position of US$9.5 million164% revenue growth in the commercial BayMedica subsidiaryVancouver, British Columbia--(Newsfile Corp. - February 13, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today reports financial result

  • Newsfile

    InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

    Vancouver, British Columbia--(Newsfile Corp. - February 9, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the appointment of Ms. Netta Jagpal, CPA, CA as Chief Financial Officer and Corporate Secretary, effective February 20, 2024. "We are excited to welcome Ms. Jagpal to InMed and are fortunate to have someone of her caliber and